Skip to main
  1. Stocks
  2. CG oncology Inc
  3. Forecast
CGON

CGON Stock Forecast & Price Target

CGON Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 50%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

CG Oncology is viewed favorably because cretostimogene has already shown strong clinical validation, including a 76% complete response rate in BOND-003 Cohort C and an 83% CR rate with Keytruda in CORE-001, while maintaining a clean safety profile with no Grade 3+ treatment-related adverse events. The company’s catalyst path is unusually clear, with PIVOT-006 topline data confirmed for November 2026, BLA completion in 4Q26, and additional durability updates expected in December 2026, any of which could expand creto’s role across intermediate-risk, high-risk BCG-unresponsive, and BCG-exposed NMIBC. Financially, CGON ended the quarter with $984.5M in cash, cash equivalents and marketable securities and a net loss of $56.9M, which supports operations through 2029 and gives it time to execute on a potentially broad commercial opportunity.

Bears say

CG Oncology is a developmental-stage biotech with extreme single-asset concentration, leaving valuation heavily dependent on cretostimogene’s clinical, regulatory, and commercial success in NMIBC. The key downside is that the company could face a CRL on its initial BLA in HRBCG-UR CIS NMIBC, disappointing data in IR/HR NMIBC, safety issues, or delays in its phase three and phase two programs, any of which could impair approval prospects and sales estimates. Competition, especially from TAR-200 and other current or future therapies, could limit market penetration and reimbursement, while weak commercial execution could force additional fundraising if operations cannot be funded from sales.

CGON has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 50% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CG oncology Inc and is not a guaranteed prediction by Public.com or investment advice.

CGON Analyst Forecast & Price Prediction

Get the latest CGON stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in CGON

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CG oncology Inc (CGON) Forecast

Analysts have given CGON a Buy based on their latest research and market trends.

According to 8 analysts, CGON has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $104.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $104.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CG oncology Inc (CGON)


CGON Analyst Forecast & Price Prediction

Get the latest CGON stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in CGON

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover CGON stock data and trends